Merck Layoffs: 54 Positions Cut at New Jersey Facility as Part of USD 3 Billion Savings Plan
Merck & Co is cutting 54 more jobs at its Rahway, New Jersey headquarters as part of a multiyear restructuring initiative aimed at achieving USD 3 billion in cost savings by 2027. 'We remain committed to New Jersey, as we continue to employ more than 8,000 people in the state,' the company said. Scroll below to know more.
Pharmaceutical giant Merck & Co. has announced a fresh round of job cuts at its global headquarters in Rahway, New Jersey, eliminating 54 positions as part of its multiyear cost-cutting initiative. According to documents filed with the New Jersey Department of Labour, the latest workforce reduction will occur in two separate phases, scheduled for December 11, 2026, and January 4, 2027. This follows a previous summer reduction affecting 88 employees at the same facility that took effect on September 4.
The staff cuts form part of Merck’s broader corporate strategy to achieve USD 3 billion in annual cost savings by 2027. The sweeping optimisation program - originally projected to impact approximately 6,000 positions globally - aims to prune spending in lower-growth areas and redirect capital toward newer product launches and pipeline development. McClatchy Layoffs: The Miami Herald Eliminates 30 Positions in Major Newsroom Cuts.
Strategic Realignment and Industry Pressures
In a statement provided to industry media, Merck characterised the reductions as “the next phase of personnel impacts related to its multiyear optimization”, reports Fierce Pharma. While specific departmental breakdowns of the latest cuts were not disclosed, the company emphasised its enduring regional footprint. "We remain committed to New Jersey, as we continue to employ more than 8,000 people in the state,” Merck said, highlighting nearly USD 3 billion invested in its New Jersey operations between 2018 and 2025. Scripps Layoffs Hit 27 Senior Executives As Broadcaster Shifts to Regional Operating Model.
The restructuring comes as major drugmakers prepare for upcoming patent expirations on key blockbuster products, including the anticipated loss of exclusivity for the immunotherapy drug Keytruda. Companies across the pharmaceutical sector are aggressively streamlining operations and adjusting staffing levels to absorb approaching revenue cliffs and shifting global demand patterns.
(The above story first appeared on LatestLY on Sep 11, 2026 03:29 PM IST. For more news and updates on politics, world, sports, entertainment and lifestyle, log on to our website latestly.com).